Skip to main content
Only direct cytotoxic targets are shown
Gene
Drug Category
Drug Class
Download CSV
Gene NCT ID Antigen/Ligand Binding Type Drug Name Drug NCI Concept Drug Category Drug Class Drug Description Drug Mechanism of Action Target Cytotoxicity Mechanism Disease Disease Type Tissue OncoTree Main Type OncoTree Name Annotation Status
ULBP2 NCT05755854 ULBP2 receptor ligand recognition Allogeneic Vγ9Vδ2 T cells CULTURED CELLS Unedited cells Adoptive cellular immunotherapy using ex vivo expanded allogeneic gamma-delta (Vγ9Vδ2) T lymphocytes that recognize phosphoantigens via BTN3A1/BTN2A1 and stress ligands via NKG2D to mediate HLA-independent cytotoxicity. Ex vivo expanded allogeneic Vγ9Vδ2 T cells that recognize tumor-associated phosphoantigens via BTN3A1/BTN2A1 and stress-induced ligands via NKG2D, enabling HLA-independent cytotoxicity through perforin/granzyme release and cytokine production. ULBP2 is an NKG2D ligand; binding to NKG2D on allogeneic Vγ9Vδ2 T cells activates them to kill target cells via perforin/granzyme-mediated cytolysis (with supportive cytokine effects). Hematologic Diseases CANCER Other Lymphatic Cancer Lymphoid Neoplasm ai
ULBP3 NCT05755854 ULBP3 receptor ligand recognition Allogeneic Vγ9Vδ2 T cells CULTURED CELLS Unedited cells Adoptive cellular immunotherapy using ex vivo expanded allogeneic gamma-delta (Vγ9Vδ2) T lymphocytes that recognize phosphoantigens via BTN3A1/BTN2A1 and stress ligands via NKG2D to mediate HLA-independent cytotoxicity. Ex vivo expanded allogeneic Vγ9Vδ2 T cells that recognize tumor-associated phosphoantigens via BTN3A1/BTN2A1 and stress-induced ligands via NKG2D, enabling HLA-independent cytotoxicity through perforin/granzyme release and cytokine production. Vγ9Vδ2 T cells express NKG2D; binding to ULBP3 on target cells activates degranulation and perforin/granzyme-mediated killing. Hematologic Diseases CANCER Other Lymphatic Cancer Lymphoid Neoplasm ai
ULBP4 NCT05755854 ULBP4 receptor ligand recognition Allogeneic Vγ9Vδ2 T cells CULTURED CELLS Unedited cells Adoptive cellular immunotherapy using ex vivo expanded allogeneic gamma-delta (Vγ9Vδ2) T lymphocytes that recognize phosphoantigens via BTN3A1/BTN2A1 and stress ligands via NKG2D to mediate HLA-independent cytotoxicity. Ex vivo expanded allogeneic Vγ9Vδ2 T cells that recognize tumor-associated phosphoantigens via BTN3A1/BTN2A1 and stress-induced ligands via NKG2D, enabling HLA-independent cytotoxicity through perforin/granzyme release and cytokine production. Vγ9Vδ2 T cells express NKG2D that binds ULBP4 on target cells, activating the T cells to release perforin and granzymes and kill the cells in an HLA-independent manner. Hematologic Diseases CANCER Other Lymphatic Cancer Lymphoid Neoplasm ai
ULBP5 NCT05755854 ULBP5 receptor ligand recognition Allogeneic Vγ9Vδ2 T cells CULTURED CELLS Unedited cells Adoptive cellular immunotherapy using ex vivo expanded allogeneic gamma-delta (Vγ9Vδ2) T lymphocytes that recognize phosphoantigens via BTN3A1/BTN2A1 and stress ligands via NKG2D to mediate HLA-independent cytotoxicity. Ex vivo expanded allogeneic Vγ9Vδ2 T cells that recognize tumor-associated phosphoantigens via BTN3A1/BTN2A1 and stress-induced ligands via NKG2D, enabling HLA-independent cytotoxicity through perforin/granzyme release and cytokine production. ULBP5 is an NKG2D ligand; Vγ9Vδ2 T cells kill ULBP5+ cells via NKG2D engagement, triggering cytotoxic degranulation (perforin/granzymes) and direct lysis. Hematologic Diseases CANCER Other Lymphatic Cancer Lymphoid Neoplasm ai
ULBP6 NCT05755854 ULBP6 receptor ligand recognition Allogeneic Vγ9Vδ2 T cells CULTURED CELLS Unedited cells Adoptive cellular immunotherapy using ex vivo expanded allogeneic gamma-delta (Vγ9Vδ2) T lymphocytes that recognize phosphoantigens via BTN3A1/BTN2A1 and stress ligands via NKG2D to mediate HLA-independent cytotoxicity. Ex vivo expanded allogeneic Vγ9Vδ2 T cells that recognize tumor-associated phosphoantigens via BTN3A1/BTN2A1 and stress-induced ligands via NKG2D, enabling HLA-independent cytotoxicity through perforin/granzyme release and cytokine production. Vγ9Vδ2 T cells express NKG2D, which recognizes ULBP6 on target cells, triggering HLA‑independent killing via perforin/granzyme release (and associated cytotoxic pathways). Hematologic Diseases CANCER Other Lymphatic Cancer Lymphoid Neoplasm ai
Displaying 876 - 880 of 3741